Patient
CRC-MET-RAS-WT-LEFT-1L-001 · Algorithm: ALGO-CRC-METASTATIC-1L
Clinical significance of mutations (ESCAT)
Tumor-board context — the engine does not use these tiers to rank tracks
| Biomarker | Variant | ESCAT | Evidence | Clinical significance | Drugs | Sources |
|---|
| No clinically actionable variants matched in this profile. |
| Biomarker | Status |
|---|
| BIO-MSI-STATUS | BIO definition in KB; no ESCAT BMA entry — verify with clinician |
| BIO-BRAF-V600E | Excluded (negative) |
| KRAS | Not in KB — ask clinician to verify |
| NRAS | Not in KB — ask clinician to verify |
Primary current-line option
- Indication
- IND-CRC-METASTATIC-1L-RAS-WT-LEFT
- Regimen
- FOLFOX + Cetuximab
- Drugs + NSZU
- Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV day 1 · IV ✓ NSZU covered
- Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV day 1 · IV ✓ NSZU covered
- 5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered
- Cetuximab (DRUG-CETUXIMAB) 500 mg/m² q2w (preferred for FOLFOX schedule; alternatively 400 mg/m² loading then 250 mg/m² weekly) · IV day 1 of each 14-d cycle · IV ✓ NSZU covered
- Reason
- Primary current-line option selected by ALGO-CRC-METASTATIC-1L at step 2; branch-driving red flag: RF-CRC-RAS-WT.
Other current-line alternatives (4 tracks)
Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.
- Indication
- IND-CRC-OLIGOMET-LIVER-LIMITED
- Regimen
- FOLFOX (mFOLFOX6)
- Drugs + NSZU
- Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
- Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV over 2h, day 1 (concurrent with oxaliplatin) · IV ✓ NSZU covered
- 5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-CRC-METASTATIC-1L-MSI-H-PEMBRO
- Regimen
- Pembrolizumab monotherapy (MSI-H mCRC 1L)
- Drugs + NSZU
- Pembrolizumab (DRUG-PEMBROLIZUMAB) 200 mg IV q3w OR 400 mg IV q6w · Until progression / unacceptable toxicity / 35 cycles (about 2 years) · IV ⚠ NSZU — not for this indication
- Hard contraindications
- CI-PEMBROLIZUMAB-AUTOIMMUNE
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV
- Regimen
- FOLFOXIRI + Bevacizumab
- Drugs + NSZU
- Irinotecan (DRUG-IRINOTECAN) 165 mg/m² · IV over 1h, day 1 · IV ✓ NSZU covered
- Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
- Leucovorin (DRUG-LEUCOVORIN) 200 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
- 5-Fluorouracil (DRUG-5-FLUOROURACIL) 3200 mg/m² CIV over 48h · Day 1-2 (no bolus) · IV ✓ NSZU covered
- Bevacizumab (DRUG-BEVACIZUMAB) 5 mg/kg · IV day 1, before chemotherapy · IV ✓ NSZU covered
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-CRC-METASTATIC-1L-FOLFOX-BEV
- Regimen
- FOLFOX + Bevacizumab
- Drugs + NSZU
- Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV day 1 · IV ✓ NSZU covered
- Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV day 1 · IV ✓ NSZU covered
- 5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered
- Bevacizumab (DRUG-BEVACIZUMAB) 5 mg/kg · IV day 1 · IV ✓ NSZU covered
- Reason
- Current-line alternative presented for HCP consideration
Why this branch was chosen
Triggers from the patient profile that fired and drove the chosen branch.
Step 2 → branch IND-CRC-METASTATIC-1L-RAS-WT-LEFT
- RF-CRC-RAS-WT ★ winner: Metastatic colorectal cancer with RAS wild-type status: KRAS exon 2 (codons 12, 13), exon 3 (codons 59, 61), exon 4 (codons 117, 146) AND NRAS exon 2/3/4 ALL wild-type by NGS or extended-RAS PCR. Defines the ~50% of mCRC eligible for anti-EGFR monoclonal antibody therapy (cetuximab, panitumumab) when combined with chemotherapy backbone. Left-sided RAS-WT mCRC particularly benefits from 1L anti-EGFR + FOLFOX/ FOLFIRI (CALGB/SWOG-80405, FIRE-3, PRIME, CRYSTAL — survival benefit driven by left-sided primaries; right-sided RAS-WT does NOT benefit and routes to bevacizumab + chemo).
SRC-NCCN-COLON-2025SRC-ESMO-COLON-2024
Pre-treatment investigations
Investigations before treatment start · critical / standard / desired · merged across tracks
| ID | Name | Priority | Category | Where to order | Needed for |
|---|
| TEST-CT-CHEST-ABDOMEN-PELVIS | CT chest + abdomen + pelvis with IV contrast | Critical | imaging | — | aggressive |
| TEST-DMMR-IHC | MMR proteins IHC (MLH1 / MSH2 / MSH6 / PMS2) | Critical | histology | CSD Lab ✓ (code TBC) | aggressive |
| TEST-MSI-PCR-OR-NGS | MSI status by PCR or NGS | Critical | histology | CSD Lab: M065
CSD Lab ✓ (code TBC) | aggressive |
| TEST-RAS-EXTENDED | RAS extended panel (KRAS exons 2-4 + NRAS exons 2-4) | Critical | histology | CSD Lab: M065 | aggressive |
| TEST-CEA | CEA | Standard | lab | — | aggressive |
| TEST-MRI-BRAIN-CONTRAST | MRI brain with contrast | Standard | imaging | — | desired (aggressive) |
| TEST-PET-CT | FDG PET/CT (whole body) | Standard | imaging | — | desired (aggressive) |
Red flags — PRO / CONTRA aggressive
PRO-AGGRESSIVE
Triggers that push toward the aggressive track
- BRAF V600E mutation in mCRC: ~8-10% prevalence, poor prognosis (median OS halved vs BRAF-WT on standard chemo). Cetuximab/panitumumab ineffective. Encorafenib + cetuximab (BEACON CRC) is preferred 2L+; some 1L data favor FOLFOXIRI + bev intensification in MSS BRAF-mutant.
RF-CRC-BRAF-V600E-POOR-PROGNOSIS
- Frailty/age profile precluding doublet-intensive or triplet chemo: ECOG ≥3, OR (age ≥80 + Charlson ≥3), OR composite (age ≥75 + albumin <3.0 + ≥2 comorbidities). Triggers de-escalation toward 5-FU/LV mono, capecitabine mono, or best supportive care.
RF-CRC-FRAILTY-AGE
- MSI-high / dMMR mCRC — treatment-defining biomarker. KEYNOTE-177 established pembrolizumab 1L over FOLFOX+bev (PFS 16.5 vs 8.2 mo). This RF intensifies toward the immunotherapy track and overrides the default RAS/BRAF-driven chemo algorithm.
RF-CRC-MSI-H-ACTIONABILITY
- Liver-limited oligometastatic colorectal cancer (CRLM, colorectal liver metastases) — a distinct subset of stage IV CRC where intensified treatment with hepatic resection (or ablation) added to systemic chemo is potentially curative. Definition (per NCCN Colon v3.2025 + ESMO CRC 2024 + EORTC 40983 / Nordlinger 2008 trial framework): ≤5 liver metastatic lesions, all R0-resectable on multidisciplinary review, no extrahepatic disease, ECOG 0-1 fitness, controllable primary tumour. Triggers MDT (medical onc + hepatobiliary surgery + radiation onc + radiology) consideration of perioperative FOLFOX (or FOLFOXIRI in selected patients) + hepatic metastasectomy. Distinct from gastroesophageal OMEC-1 oligomet (RF-OLIGOMET-DEFINITION) — CRC oligomet uses ≤5 liver lesions (not ≤3 distant), restricts to liver only (extrahepatic excluded), and HER2-positive does NOT disqualify (anti-HER2 second-line track separate from periop intensification decision).
RF-CRC-OLIGOMET-LIVER-DEFINITION
CONTRA-AGGRESSIVE
Hard contraindications to escalation
- Pembrolizumab (and other PD-1/PD-L1 inhibitors) augment T-cell responses; in patients with active autoimmunity or post-transplant immunosuppression, this can precipitate severe organ-specific flares (colitis, hepatitis, pneumonitis, transplant rejection) that may be fatal or require transplant loss.
CI-PEMBROLIZUMAB-AUTOIMMUNE
What NOT to do
Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Standard plan (IND-CRC-METASTATIC-1L-RAS-WT-LEFT)
- Do NOT use cetuximab/panitumumab in RAS-mutant CRC — bypassed signaling, no benefit
- Do NOT use cetuximab in BRAF V600E mutant — confirmed no benefit (BEACON CRC)
- Do NOT use cetuximab in right-sided RAS-WT — bevacizumab preferred per CALGB-80405
- Do NOT skip rash prophylaxis — strongly correlates with response and impacts QoL
Aggressive plan (IND-CRC-OLIGOMET-LIVER-LIMITED)
- Do NOT proceed without MDT review (medical onc + hepatobiliary surgery + radiation onc + radiology) — resectability assessment is the gate
- Do NOT offer hepatic metastasectomy without ≤5 R0-resectable liver-limited lesions + adequate future liver remnant on imaging review
- Do NOT include extrahepatic disease (lung, peritoneal, distant LN, brain) — these are explicit exclusions and route to standard 1L metastatic CRC management
- Do NOT continue bevacizumab perioperatively — hold ≥6 weeks before hepatectomy due to wound-healing / hepatic-regeneration risk; resume post-recovery if indicated
- Do NOT initiate during ongoing GI bleed / obstruction / perforation — emergency management first (RF-CRC-EMERGENCY-OBSTRUCTION-PERFORATION)
- Do NOT default to non-MDT single-surgeon decision — refer to a hepatobiliary surgeon at an appropriate-volume centre
Aggressive plan (IND-CRC-METASTATIC-1L-MSI-H-PEMBRO)
- Do NOT start FOLFOX/FOLFIRI ± bev/cetux in MSI-H mCRC 1L — substantial PFS loss vs ICI
- Do NOT continue pembrolizumab through Grade 3+ immune-related AE without specialist consultation
- Do NOT start pembrolizumab without prior MSI/dMMR confirmation by validated assay
Aggressive plan (IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV)
- Do NOT use in ECOG PS ≥ 2 — toxicity unacceptable; use doublet (FOLFOX+bev or FOLFIRI+bev)
- Do NOT use in MSI-H/dMMR patients — pembrolizumab 1L is preferred (KEYNOTE-177)
- Do NOT use without G-CSF prophylaxis — neutropenia rate ~50%
- Do NOT omit irinotecan pre-medication (atropine — cholinergic prevention)
- Do NOT add anti-EGFR (cetuximab/panitumumab) — triplet + anti-EGFR vs triplet + bev not superior per MACBETH/VOLFI; use one or the other
- Do NOT continue past disease progression — switch promptly to 2L
Aggressive plan (IND-CRC-METASTATIC-1L-FOLFOX-BEV)
- Do NOT initiate within 28 days of major surgery (perforation / dehiscence risk)
- Do NOT continue bevacizumab through uncontrolled HTN >160/100
- Do NOT use in patients with high-risk varices / active hemoptysis
Timeline
Treatment timeline — derived from regimen + monitoring schedule
Standard plan
Induction · FOLFOX + Cetuximab
14-day cycles × Until progression / unacceptable toxicity
Aggressive plan
Induction · FOLFOX (mFOLFOX6)
14-day cycles × 12 cycles (6 mo) for adjuvant stage III; until progression / unacceptable toxicity for metastatic; 4 cycles (8 wk) periop trials
Aggressive plan
Induction · Pembrolizumab monotherapy (MSI-H mCRC 1L)
21-day cycles × Until progression / unacceptable toxicity / max 35 cycles per KEYNOTE-177
Aggressive plan
Induction · FOLFOXIRI + Bevacizumab
14-day cycles × Until progression / unacceptable toxicity; consider de-escalation after 4-6 months
Aggressive plan
Induction · FOLFOX + Bevacizumab
14-day cycles × Until progression / unacceptable toxicity (mCRC 1L)
MDT brief
Discussion questions (2, 1 blocking)
OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
BLOCKING OQ-BIOMARKER-RAS-MUTATION
What is the status of RAS mutation status (KRAS / NRAS exons 2-4) (BIO-RAS-MUTATION)? It is required by track(s): IND-CRC-METASTATIC-1L-RAS-WT-LEFT. Expected value: RAS-WT.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ molecular_geneticist
MDT talk tree (3 steps)
| # | Owner | Topic | Action |
|---|
| 1 | molecular_geneticist | Biomarker status BLOCKING | What is the status of RAS mutation status (KRAS / NRAS exons 2-4) (BIO-RAS-MUTATION)? It is required by track(s): IND-CRC-METASTATIC-1L-RAS-WT-LEFT. Expected value: RAS-WT. |
| 2 | hematologist | Staging / disease burden | What is the current LDH? Marker of tumor burden and transformation. |
| 3 | clinical_pharmacist | Specialist review | Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication. |
Skills (recommended) — for consideration (2)
- Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
- Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
Owns: OQ-BIOMARKER-RAS-MUTATION
Data quality
Incomplete for default-track review. Default-track review is incomplete until required biomarker gaps are resolved.
- Biomarker coverage: 1/2 known (50%), 1 missing, 1 default-track gaps
- Unevaluated RedFlags: RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK, RF-COWDEN-CONFIRMED-CARRIER, RF-COWDEN-FAMILY-HISTORY-SUSPICION, RF-CRC-EMERGENCY-OBSTRUCTION-PERFORATION, RF-CRC-FRAILTY-AGE, RF-CRC-HER2-AMP-ACTIONABLE, RF-CRC-INFECTION-SCREENING, RF-CRC-OLIGOMET-LIVER-DEFINITION, RF-CRC-RAS-MUTANT, RF-CRC-TRANSFORMATION-PROGRESSION, RF-FAP-CONFIRMED-CARRIER, RF-FAP-FAMILY-HISTORY-SUSPICION, RF-IBD-CRC-PREVENTION, RF-LIFESTYLE-ALCOHOL-CANCER-PREVENTION, RF-LIFESTYLE-HIGH-RED-MEAT-CRC-PREVENTION, RF-LIFESTYLE-LOW-CALCIUM-VIT-D-CRC-PREVENTION, RF-LIFESTYLE-LOW-FIBER-CRC-PREVENTION, RF-LIFESTYLE-LOW-MEDITERRANEAN-DIET-PREVENTION, RF-LIFESTYLE-OBESITY-CANCER-PREVENTION, RF-LIFESTYLE-PROCESSED-MEAT-PREVENTION, RF-LIFESTYLE-SEDENTARY-PREVENTION, RF-LYNCH-CONFIRMED-CARRIER, RF-LYNCH-FAMILY-HISTORY-SUSPICION, RF-OCC-FIREFIGHTER-PREVENTION, RF-PEUTZ-JEGHERS-CONFIRMED-CARRIER, RF-PEUTZ-JEGHERS-FAMILY-HISTORY-SUSPICION, RF-PSC-CHOLANGIOCARCINOMA-PREVENTION
| Missing biomarker | Label | MDT owner | Default track | Required by | Next action |
|---|
BIO-RAS-MUTATION | RAS mutation status (KRAS / NRAS exons 2-4) | molecular_geneticist | yes | IND-CRC-METASTATIC-1L-RAS-WT-LEFT | Verify result, method, specimen, and report date before sign-off. Expected/constraint: RAS-WT |
Technical MDT skill metadata (2/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
| Specialist | skill_id | Version | Last reviewed | Sign-offs | Domain |
|---|
| Cellular therapy specialist (CAR-T) | cellular_therapy_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
| Clinical pharmacist | clinical_pharmacist | v0.1.0 | 2026-04-25 | 0 | clinical_pharmacy |
| Hematologist / oncohematologist | hematologist | v0.1.0 | 2026-04-25 | 0 | hematology_oncology |
| Hematopathologist (lymphoma / leukemia / myeloma) | hematopathologist | v0.1.0 | 2026-04-25 | 0 | hematopathology |
| Infectious disease / hepatology | infectious_disease_hepatology | v0.1.0 | 2026-04-25 | 0 | infectious_diseases |
| Medical oncologist (solid-tumor chemotherapist) | medical_oncologist | v0.1.0 | 2026-04-25 | 0 | solid_oncology |
| Molecular geneticist / molecular oncologist | molecular_geneticist | v0.1.0 | 2026-04-25 | 0 | molecular_oncology |
| Palliative care | palliative_care | v0.1.0 | 2026-04-25 | 0 | palliative_care |
| Pathologist (general) | pathologist | v0.1.0 | 2026-04-25 | 0 | pathology |
| Primary care / family physician | primary_care | v0.1.0 | 2026-04-25 | 0 | primary_care |
| Psycho-oncologist | psychologist | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Radiation oncologist | radiation_oncologist | v0.1.0 | 2026-04-25 | 0 | radiation_oncology |
| Radiologist | radiologist | v0.1.0 | 2026-04-25 | 0 | diagnostic_imaging |
| Social worker / case manager | social_worker_case_manager | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Surgical oncologist | surgical_oncologist | v0.1.0 | 2026-04-25 | 0 | surgical_oncology |
| Transplant specialist (BMT) | transplant_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
Sources cited
- SRC-ESMO-COLON-2024: ESMO CRC Clinical Practice Guideline (2024)
- SRC-ESMO-CRC-2024: ESMO colorectal cancer guideline (2024) (TODO: confirm citation) ()
- SRC-KEYNOTE-177-ANDRE-2020: Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer (2020)
- SRC-NCCN-COLON-2025: NCCN Colon / Rectal Cancer (v.4.2025)
- SRC-TRIBE-LOUPAKIS-2014: FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Treatment of Metastatic Colorectal Cancer (2014)
- SRC-TRIBE2-CREMOLINI-2020: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE2 study (2020)
Experimental options (clinical trials)
Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-06-27.
| NCT | Title | Phase | Status | Sponsor | UA | Signals | Eligibility (excerpt) |
|---|
| NCT07112690 | Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment | NA | RECRUITING | — | Small N (<50) Single country | |
| NCT05929820 | Impact of Protect Your Colon™ on CRC Screening | NA | RECRUITING | — | Single country | |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | PHASE1 | RECRUITING | — | Phase 1 only Small N (<50) Single country | |
| NCT06649123 | Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer | N/A | RECRUITING | — | Single country | |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | PHASE1 | RECRUITING | — | Phase 1 only Single country | |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | PHASE4 | RECRUITING | — | — | |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | PHASE1 / PHASE2 | RECRUITING | — | Single country | |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | N/A | RECRUITING | — | Surrogate endpoint only Single country | |
| NCT07150247 | Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer | PHASE2 | RECRUITING | — | Small N (<50) Surrogate endpoint only Single country | |
| NCT05850130 | Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients | NA | RECRUITING | — | Single country | |
Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.
Option availability in Ukraine
Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
| Option | UA registration | NSZU | Cost orientation | Access pathway |
|---|
| Standard plan FOLFOX + Cetuximab (REG-FOLFOX-CETUX) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan FOLFOX (mFOLFOX6) (REG-FOLFOX) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan Pembrolizumab monotherapy (MSI-H mCRC 1L) (REG-PEMBROLIZUMAB-MSI-MONO) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan FOLFOXIRI + Bevacizumab (REG-FOLFOXIRI-BEV) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan FOLFOX + Bevacizumab (REG-FOLFOX-BEV) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Trial · NCT07112690 Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05929820 Impact of Protect Your Colon™ on CRC Screening No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07417488 GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06649123 Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06307249 Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06562543 A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07432633 [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT02838836 Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07150247 Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05850130 Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-06-27.